Table 2. Expression of CXCR3 or CXCR4 on... | American Society of Hematology

Table 2.

Expression of CXCR3 or CXCR4 on Vδ1 or Vδ2 T cells in peripheral blood of HIV-1—infected patients and healthy donors

	Vδ2⁺	Vδ2⁺ CXCR3⁺	Vδ2⁺ CXCR4⁺	Vδ1⁺	Vδ1⁺ CXCR3⁺	Vδ1⁺ CXCR4⁺
Patients
1	1.0	0.9	0.9	1.0	0.8	1.0
2	1.6	1.5	1.6	1.2	1.0	1.2
3	0.7	0.6	0.7	1.4	1.3	1.2
4	1.9	1.8	1.7	2.2	1.8	2.0
5	0.7	0.7	0.7	4.2	3.2	3.6
6	2.7	2.8	2.3	4.1	2.0	3.9
7	0.3	0.2	0.3	1.0	0.9	1.1
8	3.8	2.8	3.1	2.2	1.6	1.8
9	0.4	0.3	0.4	2.3	2.0	1.9
10	2.4	2.3	2.6	2.9	1.9	2.9
11	0.3	0.2	0.3	8.8	4.3	8.6
12	1.3	1.3	1.2	2.7	1.7	1.4
13	1.1	1.0	1.3	2.3	1.6	2.0
14	3.0	1.9	1.6	1.2	1.0	1.2
15	1.0	0.9	0.7	2.2	1.3	2.2
16	3.2	2.4	2.0	4.1	2.3	3.9
17	3.5	2.2	1.0	4.2	2.0	1.7
18	4.0	3.3	1.1	9.2	2.9	4.8
19	2.0	1.9	1.0	0.9	0.6	0.4
20	1.8	1.4	1.3	4.4	3.3	3.3
21	3.4	2.9	2.6	9.3	7.3	6.4
22	1.4	1.4	1.6	2.7	1.7	2.7
23	0.4	0.2	0.2	2.0	0.8	0.6
24	4.8	3.8	4.8	3.0	2.9	2.0
25	3.3	2.5	3.2	1.8	1.5	1.7
26	2.2	0.8	0.4	3.6	1.2	0.7
27	2.0	2.0	2.2	2.7	1.7	2.2
28	1.4	0.7	1.4	4.0	2.8	3.9
Healthy donors
1	0.9	0.8	0.2	1.9	0.8	1.6
2	1.3	1.2	0.3	1.2	0.6	1.2
3	3.1	2.8	0.7	0.9	0.6	0.8
4	2.9	2.2	0.6	0.6	0.2	0.5
5	0.8	0.6	0.1	0.5	0.2	0.5
6	1.4	1.0	0.3	2.3	0.9	2.1
7	2.6	2.2	0.6	0.8	0.2	0.6
8	2.0	1.9	0.2	0.2	0.1	0.1
9	2.3	2.0	0.3	2.2	1.0	2.1
10	1.6	1.2	0.9	2.0	0.9	1.9
11	2.8	2.0	0.3	0.8	0.4	0.7
12	1.7	1.3	0.2	1.8	1.0	1.7
13	1.8	1.0	1.1	1.7	0.9	0.6
14	1.9	1.8	0.5	1.1	0.5	0.9
15	2.4	1.6	0.2	0.4	0.2	0.4

	Vδ2⁺	Vδ2⁺ CXCR3⁺	Vδ2⁺ CXCR4⁺	Vδ1⁺	Vδ1⁺ CXCR3⁺	Vδ1⁺ CXCR4⁺
Patients
1	1.0	0.9	0.9	1.0	0.8	1.0
2	1.6	1.5	1.6	1.2	1.0	1.2
3	0.7	0.6	0.7	1.4	1.3	1.2
4	1.9	1.8	1.7	2.2	1.8	2.0
5	0.7	0.7	0.7	4.2	3.2	3.6
6	2.7	2.8	2.3	4.1	2.0	3.9
7	0.3	0.2	0.3	1.0	0.9	1.1
8	3.8	2.8	3.1	2.2	1.6	1.8
9	0.4	0.3	0.4	2.3	2.0	1.9
10	2.4	2.3	2.6	2.9	1.9	2.9
11	0.3	0.2	0.3	8.8	4.3	8.6
12	1.3	1.3	1.2	2.7	1.7	1.4
13	1.1	1.0	1.3	2.3	1.6	2.0
14	3.0	1.9	1.6	1.2	1.0	1.2
15	1.0	0.9	0.7	2.2	1.3	2.2
16	3.2	2.4	2.0	4.1	2.3	3.9
17	3.5	2.2	1.0	4.2	2.0	1.7
18	4.0	3.3	1.1	9.2	2.9	4.8
19	2.0	1.9	1.0	0.9	0.6	0.4
20	1.8	1.4	1.3	4.4	3.3	3.3
21	3.4	2.9	2.6	9.3	7.3	6.4
22	1.4	1.4	1.6	2.7	1.7	2.7
23	0.4	0.2	0.2	2.0	0.8	0.6
24	4.8	3.8	4.8	3.0	2.9	2.0
25	3.3	2.5	3.2	1.8	1.5	1.7
26	2.2	0.8	0.4	3.6	1.2	0.7
27	2.0	2.0	2.2	2.7	1.7	2.2
28	1.4	0.7	1.4	4.0	2.8	3.9
Healthy donors
1	0.9	0.8	0.2	1.9	0.8	1.6
2	1.3	1.2	0.3	1.2	0.6	1.2
3	3.1	2.8	0.7	0.9	0.6	0.8
4	2.9	2.2	0.6	0.6	0.2	0.5
5	0.8	0.6	0.1	0.5	0.2	0.5
6	1.4	1.0	0.3	2.3	0.9	2.1
7	2.6	2.2	0.6	0.8	0.2	0.6
8	2.0	1.9	0.2	0.2	0.1	0.1
9	2.3	2.0	0.3	2.2	1.0	2.1
10	1.6	1.2	0.9	2.0	0.9	1.9
11	2.8	2.0	0.3	0.8	0.4	0.7
12	1.7	1.3	0.2	1.8	1.0	1.7
13	1.8	1.0	1.1	1.7	0.9	0.6
14	1.9	1.8	0.5	1.1	0.5	0.9
15	2.4	1.6	0.2	0.4	0.2	0.4

Direct immunofluorescence on whole blood of HIV-1-infected patients was performed with PE-anti-CXCR3 or -CXCR4 mAbs, and the anti-Vδ1 A13 or the anti-Vδ2 BB3 mAbs were labeled using the Zenon Alexafluor 488 mouse IgG1 Labeling Kit. Samples were analyzed on a flow cytometer equipped with an argon ion laser exciting PE and Alexafluor at 488 nm and gated on lymphocytes. Data are expressed as percentage of positive or double-positive cells.

View Large

This Feature Is Available To Subscribers Only